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34a Sunday, February 8, 2015scale motions that are quenched upon PPACK binding. TROSYHahn-echo and
relaxation dispersion experiments reveal a large number of residues throughout
the protein undergoing temporally correlated ms-ms motions. These include the
Naþ-binding loop and the b-strand connecting exosite 1 and the active site,
both of which are implicated in allosteric coupling of effector binding sites
with the active site. The results show a network of slowly exchanging residues
extends through the entire apo-thrombin molecule.
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Enzyme activity is essential for almost all aspects of life. With completely
sequenced genomes, the full complement of enzymes in an organism can be
defined, and 3D structures have been determined for many enzyme families.
Traditionally each enzyme has been studied individually, but as more enzymes
are characterised it is now timely to revisit the molecular basis of catalysis, by
comparing different enzymes and their mechanisms, and to consider how com-
plex pathways and networks may have evolved. New approaches to understand-
ing enzymes mechanisms and how enzyme families evolve functional diversity
will be described.
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More than 300 mutations in the b myosin heavy chain gene cause a variety of
both skeletal and cardiomyopathies. Most of these mutations are autosomal
dominant; thus most patients have both mutant and wild type myosin in their
heart and skeletal muscle. The mutations are distributed throughout the mole-
cule, including the motor domain and the a helical coiled coil rod. We hypoth-
esize that the mechanisms of pathogenesis are distinct between mutations in
these two functional domains. We have adopted a number of approaches to
define the functional impact of these mutations on myosin function. For study-
ing mutations in the motor domain, we produce recombinant human cardiac
myosin motors and carry out in vitro biochemical and biophysical analysis.
Historically, studies investigating the effects of myosin motor domain muta-
tions have been performed on a wide variety of myosins from many species
and myosin isoforms. Likely as a result of this, results have been confusing.
We have begun analyzing two mutations in the motor domain that cause hyper-
trophic cardiomyopathy (R403Q and R453C) and have found that each muta-
tion affects myosin motor function differently. To study the impact of
mutations in the rod domain, we carry out biophysical analyses on purified pro-
tein and perform live cell imaging to determine the effects of mutations on
sarcomere integrity. We have also found that myosin rod mutations that cause
Laing distal myopathy have distinct phenotypes that include accumulation into
aggregates and crystalline arrays in cells. To attempt to develop therapeutics for
such single nucleotide mutations without affecting the wild type myosin, we are
developing allele-specific silencing approaches.
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The giant protein titin is responsible for the elasticity of striated muscle cells
and engages in both mechanical and signaling functions of the heart. TTN,which encodes titin, is a major human disease gene. Mutations in the
myosin-bound part of titin account for a large share of familial cases of dilated
cardiomyopathy. The elasticity of cardiac titin, which resides in the molecule’s
I-band region, is regulated by various means, including titin-isoform switching,
phosphorylation of unique spring elements by different kinases, and oxidative
stress-related alterations to titin. In failing human hearts, titin is hypo-
phosphorylated, which appears to be due in part to a phosphorylation deficit
at the cardiac-specific N2-B unique sequence and likely contributes to a
pathologically increased (titin-based) diastolic stiffness. A recent focus has
been the regulation of the mechanical properties of the immunoglobulin-like
(Ig-)domains in the titin spring segment. New evidence suggests that a low
but non-negligible number of Ig-domains unfolds-refolds within the physiolog-
ical sarcomere-length range. These Ig-domains are targeted via an oxidative
stress-related mechanism recently identified by single-molecule AFM force
spectroscopy. If unfolded, the Ig-domains expose cryptic cysteines, which in
the presence of oxidized glutathione can become S-glutathionylated. The pres-
ence of mixed disulfide(s) with glutathione weakens the mechanical stability of
the unfolded Ig-domains and prevents their refolding, thus reducing titin stiff-
ness. Incubation of stretched (skinned) human cardiomyocytes with oxidized
glutathione significantly lowered their passive tension, and the effect was fully
reversible on incubation with a reductant. In experimental mouse hearts
exposed to oxidative stress (0.1 mM H2O2), I-band Ig-domains of titin were
identified as preferential targets of oxidation using ICAT labeling/mass spec-
trometry. These findings establish that disrupted Ig-folding-unfolding dy-
namics can cause sustained but reversible changes to titin elasticity, which
may also be relevant in heart disease.
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Hypertrophic cardiomyopathy (HCM) is mainly characterized by left ventricular
hypertrophy (LVH), diastolic dysfunction and increased interstitial fibrosis.
HCM has an estimated prevalence in a young adult population of 1:500 and is
the leading cause of sudden cardiac death in young athletes. HCM is transmitted
in an autosomal-dominant fashion and often caused by mutations in MYBPC3,
encoding cardiac myosin-binding protein C (cMyBP-C). Most MYBPC3 muta-
tions result in truncated proteins. Findings in humans and in cat/mouse models
indicate that haploinsufficiency is the most prevalent HCM mechanism. The
presence of double truncating MYBPC3 mutations in infants has been shown
to result in severe heart failure and death within 1 year. One of our goals is to
prevent the development of the severe cardiac disease phenotype by gene ther-
apy.We developed a mouse model that genetically mimics some human neonatal
forms of HCM. The Mybpc3-targeted knock-in (KI) mice carry a homozygous
G>A transition in exon 6, resulting in 3 different aberrant mRNAs and proteins.
I will present the results of the different gene therapy approaches we performed
in this mouse model, which include 50-trans-splicing, exon skipping and over-
expression. The different strategies were evaluated in isolated cardiac myo-
cytes, engineered heart tissue or in vivo in the homozygous KI mice. With
the 3 approaches, we provided proof-of-concept studies that paved the way
to evaluate the concept in larger animal models and then in severe forms of
human neonatal cardioymyopathies.
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In many ways, sarcomeric cardiomyopathies represent the most ‘‘biophysi-
cal’’ of disorders in that many of the known mutations, especially those linked
to the components of the regulatory thin filament alter the biophysical prop-
erties of the sarcomere, leading to a complex and often severe human cardio-
myopathy. Despite extensive research, developing robust mechanistic links
between sarcomeric dysfunction caused by independent mutations and cardiac
performance has proven surprisingly elusive. On the biophysical side of the
question, newer approaches including computation and structural methodolo-
gies performed on fully reconstituted systems now provide more resolution
into the inherently dynamic, allosteric effects of mutations on the sarcomeric
machinery. On the clinical side, in recent years it has become clear that the
